|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007138,
umls-concept:C0013216,
umls-concept:C0030705,
umls-concept:C0069515,
umls-concept:C0205179,
umls-concept:C0220901,
umls-concept:C0242957,
umls-concept:C0597879,
umls-concept:C1517927,
umls-concept:C1522673,
umls-concept:C1533716,
umls-concept:C1999230
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2007-10-17
|
|
pubmed:abstractText |
To evaluate the impact of HER2 immunoreactivity on clinical outcome in locally advanced urothelial carcinoma patients who received surgery alone, or methotrexate, vinblastine, epirubicin, and cisplatin (M-VEC) as adjuvant chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1423-0399
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2007 S. Karger AG, Basel.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
79
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
210-6
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17940352-Adult,
pubmed-meshheading:17940352-Aged,
pubmed-meshheading:17940352-Aged, 80 and over,
pubmed-meshheading:17940352-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17940352-Carcinoma,
pubmed-meshheading:17940352-Chemotherapy, Adjuvant,
pubmed-meshheading:17940352-Cisplatin,
pubmed-meshheading:17940352-Disease-Free Survival,
pubmed-meshheading:17940352-Epirubicin,
pubmed-meshheading:17940352-Female,
pubmed-meshheading:17940352-Follow-Up Studies,
pubmed-meshheading:17940352-Humans,
pubmed-meshheading:17940352-Immunohistochemistry,
pubmed-meshheading:17940352-Lymphatic Metastasis,
pubmed-meshheading:17940352-Male,
pubmed-meshheading:17940352-Methotrexate,
pubmed-meshheading:17940352-Middle Aged,
pubmed-meshheading:17940352-Proportional Hazards Models,
pubmed-meshheading:17940352-Receptor, erbB-2,
pubmed-meshheading:17940352-Time Factors,
pubmed-meshheading:17940352-Treatment Outcome,
pubmed-meshheading:17940352-Urinary Bladder Neoplasms,
pubmed-meshheading:17940352-Urothelium,
pubmed-meshheading:17940352-Vinblastine
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
|
|
pubmed:affiliation |
Institute of Clinical Medicine, Department of Urology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Evaluation Studies
|
